Free provider profile
PAVAN REDDY, M.D.
Need more providers like PAVAN REDDY?
See the count and top 3 free, ranked by Medicare billing. Full list $29, included with membership.
Rep intel
What PAVAN REDDY prescribes and who else does
Top Medicare Part D drugs by claims (public CMS data):
- Pomalyst
- Ninlaro
- Verzenio
- Bosulif
- Tagrisso
Your next referral list starts here
Provider + market indicator
A combined screening indicator—not a provider fraud-risk score. Local plan ratings describe the surrounding market, not this provider’s quality, plan membership or wrongdoing.
Comparing current CMS billing with peers and checking OIG and plan ratings… A new peer comparison can take about a minute.
Practice contact card
Practice phone
316-262-4467
Fax
316-262-3762
Practice address
818 N EMPORIA ST STE 403, WICHITA, KS, 67214
- Registry updated
- 2026-04-02
- NPI issued
- 2006-04-04
- RepVector retrieved
- 11/20/2026
A recent retrieval can still contain an old address if the provider has not updated their registry record. Website email checks show their own date under Find email.
Registry record
Source: CMS NPPES registry.
818 N EMPORIA ST STE 403, WICHITA, KS, 67214
316-262-4467
2 practice locations listed
Enumerated 2006-04-04
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 2 practice locations listed — multi-site footprint.
- — Record updated within the last year.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
4,234
Medicare patients
669
Part D drug cost
$5,769,090
Brand-name share
18.5%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Pomalyst (Pomalidomide) | 43 | $973,947 |
| Bosulif (Bosutinib) | 25 | $534,764 |
| Ninlaro (Ixazomib Citrate) | 40 | $522,647 |
| Verzenio (Abemaciclib) | 27 | $401,694 |
| Tagrisso (Osimertinib Mesylate) | 22 | $373,112 |
| Cabometyx (Cabozantinib S-Malate) | 12 | $302,740 |
| Brukinsa (Zanubrutinib) | 20 | $301,930 |
| Jakafi (Ruxolitinib Phosphate) | 15 | $259,580 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Latest Medicare Part B billing
CMS Physician and Other Practitioners, by Provider and Service. New published billing years are detected daily, using the same release as the Billing analyst and risk maps.
Loading the latest published CMS billing file…
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
Checking Open Payments…
Industry payments across KS — which companies pay providers there.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.
